CAS: 35654-56-9; 4-Chloro-6,7-Dimethoxyquinoline

上下游产品

6,7-dimethoxyquinoline-4-ol 1,4-dihydro-6,7-dimethoxy-4-oxoquinoline [[(3,4-Dimethoxyphenyl)amino]methylene]malonic acid,diethyl ester ethyl 6,7-dimethoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylate 6783Ki6783 75CA75 6,7dimethoxy4(4nitrophenoxy)quinoline 4-(2-fluoro-4-nitro-phenoxy)-6,7-dimethoxy-quinoline

3,4-二甲氧基苯胺置于sodium Hydroxide,三氯氧磷体系中,用 甲醇,二苯醚 作为反应溶剂,化学反应 4.5H,反应生成 4-氯-6,7-二甲氧基喹啉
参考文献:鉴定pdgf受体自身磷酸化的有效和选择性抑制剂.
标题:鉴定pdgf受体自身磷酸化的有效和选择性抑制剂.
摘要:我们报告了喹啉和喹唑啉衍生物的结构活性关系,其中包括尿素,硫脲,氨基甲酸酯和酰基硫脲基团,作为血小板衍生生长因子(pdgf)受体自身磷酸化的抑制剂.我们以前的研究表明,包括尿素,硫脲和氨基甲酸酯基团在内的喹啉和喹唑啉衍生物是作为pdgf受体自磷酸化抑制剂的高效化合物,但这些化合物在pdgf受体和c-Kit受体之间没有受体选择性.作为进一步合成和生物学评估的结果,我们发现喹啉和喹唑啉-酰基硫脲衍生物不仅显示出对pdgf受体的非常好抑制活性,而且还显示了pdgf受体与c-Kit受体之间的受体选择性.此外,N-{4-[(6,7-二甲氧基-4-喹啉基)氧基]苯基}-N'-(2-甲基苯甲酰基)硫脲在使用大鼠颈动脉球囊损伤模型的体内试验中显示出有效的口服功效.因此,可以预期喹啉和喹唑啉-酰基硫脲衍生物具有作为治疗再狭窄的治疗剂的潜力.
DOI:10.1021/jm0506423

专利信息

专利号:CN-114250479-B
优先权日:2021-12-11
标 题 :A new method for the synthesis of alkyl-substituted nitrogen-containing heterocycles catalyzed by cerium salts

专利号:US-9861636-B2
优先权日:2014-04-29
标题 :Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
发明人：HE WEI
权利人:HE WEI; ZHEJIANG DTRM BIOPHARMA CO LTD
摘要:Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

专利号:US-9242991-B2
优先权日:2010-07-14
标题:Substituted fused heterocycles as c-Met tyrosine kinase inhibitors
发明人：HU SHAOJING; WANG FEI; LONG WEI; SHEN XIAOYAN; TAN FENLAI; WANG YINXIANG
权利人:HU SHAOJING; WANG FEI; LONG WEI; SHEN XIAOYAN; TAN FENLAI; WANG YINXIANG; BETTA PHARMACEUTICALS CO LTD
摘要:This invention relates to certain novel fused quinazoline derivatives (Formula I) as c-Met inhibitors which is shown as formula I, their synthesis and their use for treating a c-Met mediated disorder. More particularly, this invention is directed to fused heterocyclic derivatives useful inhibitors of c-Met, methods for producing such compounds and methods for treating as c-Met mediated disorder